Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01674205 · ClinicalTrials.gov registry record · Phase 1
Study of Immune Responses in Healthy Adults Receiving Live Influenza Virus Vaccines
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT01674205 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 36 participants.
The verdict
NCT01674205, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This study seeks to understand the host factors that affect the replication and immune response of seasonal and candidate pandemic live attenuated influenza vaccine (LAIV) in humans and to develop biomarkers that can predict the viral shedding and immune response to LAIVs.
Interventions
- BIOLOGICAL A/swine/Missouri/4296424/2006 (H2N3) x A/Ann Arbor/6/60 ca (H2N3 MO 2006/AA ca)
- BIOLOGICAL A/chicken/Hong Kong/G9/97 (H9N2) x A/Ann Arbor/6/60 ca (H9N2 G9/AA ca)
- BIOLOGICAL 2012-2013 trivalent seasonal live attenuated influenza vaccine (FluMist®)
- BIOLOGICAL Vaccine placebo (Leibovitz-15 [L-15])
- BIOLOGICAL Vaccine placebo (FluMist®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01674205
The ClinicalTrials.gov registry entry for NCT01674205 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which A/swine/Missouri/4296424/2006 (H2N3) x A/Ann Arbor/6/60 ca (H2N3 MO 2006/AA ca) is the first listed.
NCT01674205 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01674205 about?
NCT01674205 is a clinical study titled "Study of Immune Responses in Healthy Adults Receiving Live Influenza Virus Vaccines". This study seeks to understand the host factors that affect the replication and immune response of seasonal and candidate pandemic live attenuated influenza vaccine (LAIV) in humans and to develop biomarkers that can predict the viral shedding and immune response to LAIVs.
What is the current status of trial NCT01674205?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2012-09. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01674205?
The interventions under investigation include: A/swine/Missouri/4296424/2006 (H2N3) x A/Ann Arbor/6/60 ca (H2N3 MO 2006/AA ca) (BIOLOGICAL), A/chicken/Hong Kong/G9/97 (H9N2) x A/Ann Arbor/6/60 ca (H9N2 G9/AA ca) (BIOLOGICAL), 2012-2013 trivalent seasonal live attenuated influenza vaccine (FluMist®) (BIOLOGICAL), Vaccine placebo (Leibovitz-15 [L-15]) (BIOLOGICAL), Vaccine placebo (FluMist®) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01674205?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.